Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Idiopathic Membranous Nephropathy
NCT01762852Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Apr 2013
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of belimumab in idiopathic membranous nephropathy (IMN), sponsored by GSK. Planned start Apr 2013; status: withdrawn.
02
Drugs
belimumab
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT01762852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01762852.